Skip to content
Home / News |

ReNeuron Shares Surge 10.2% as Phase IIa Trial Begins

Reneuron logo
Simon Mugo

Shares of ReNeuron Group Plc (LON: RENE) today surged 10.2% after the company announced that it had started extended phase IIa trials of its hRPC cell therapy for retinitis pigmentosa, a degenerative eye condition.

The company which specialises in stem-cell research today announced that it had started dosing procedures within the US and that the expanded phase IIa trial will include at least nine people who will receive higher doses of the hRPC cell therapy.

Ten patients are already participating in the study, which will raise the total number to nineteen patients, distributed across the UK and America. Further results will be published in the next 12 months.

X testing X
WELCOME BONUS - Free Share Bundle When You Invest £50! Get up to £500 cashback for investing with IG.
Invest in 15,000+ shares and ETFs. Open an account now, invest at least £50, and you’ll get a free share bundle worth between £40 and £200. T&Cs apply.
5.0
Open Account Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 68% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work, and whether you can afford to take the high risk of losing your money.

The hRPC treatment has been granted orphan drug status in both the US and Europe with the US Food & Drug Administration (FDA) giving it fast-track status, which bodes well for the treatment.

ReNeuron share price

Tradingview chart of Reneuron share price 10092020

ReNeuron shares today surged 10.2% to trade at 99p having ended Wednesday’s session trading at 89.8p.

People who read this also read:

Simon Mugo
Simon Mugo
Contributor

Simon ist Autor und Analyst für den Bereich Finanzwesen und blickt auf über sechs Jahre professionelle Erfahrung als Trader zurück. Er absolvierte einen Bachelor in Mathematik und Informatik und hat eine Leidenschaft für die Finanzmärkte. Simon handelt FX, Rohstoffe und Aktien. Er konzentriert sich auf Price Action Trading.